ImmunoGen, Inc. Profile Avatar - Palmy Investing

ImmunoGen, Inc.

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase…

Biotechnology
US, Waltham [HQ]

Government Awards Analysis Beta

Obligations Over-Time

Awards
Obligations

ImmunoGen, Inc. has no obligation with a government/award agency.

Latest Obligations

Contracts
$ 0.0
0.0 IDVs
$ 0.0
Direct Payments
$ 0.0
Grants
$ 0.0
Loans
$ 0.0
Other Payments
$ 0.0
vs. Previous FY
Contracts
$ 0.0
IDVs
$ 0.0
Direct Payments
$ 0.0
Grants
$ 0.0
Loans
$ 0.0
Other Payments
$ 0.0
YoY Trends
  • No trends presentable at the moment.

Spending By Type

Awards
Obligations
Contracts IDV Contracts Grants Loans Direct Other

ImmunoGen, Inc. can't present spending by time.

End of IMGN's Analysis
CIK: 855654 CUSIP: 45253H101 ISIN: US45253H1014 LEI: - UEI: -
Secondary Listings